Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentaryon these stories, subscribe to the This Week in Cardiology podcast.
For the week ending June 5, 2020, John Mandrola, MD comments on the following news and features stories.
When I recorded last week there were 1.75 million cases in the United States. Today there are roughly 1.9 million. The rate of growth of 1.08x is the same as last week. US deaths last week were 102,000 and this week they are 109,000; this rate of rise identical to last weeks, at 1.06x.
This is a cardiology podcast and I will discuss cardiology topics today but it seems tone-deaf and irreverent to drone on without acknowledging the widespread protests about racial injustice.
Its impossible for people like me to feel the injustices felt by racial minorities. My friend Dr. Andrew Foy, a cardiologist and researcher in Hershey, Pennsylvania, has a unique point of view of the black and Hispanic communities because he promotes boxing. Andrew sent me a slide he made and posted on social media showing the percentage of black and Hispanic graduates of medical school vs the percentage of blacks and Hispanics in the US population. It showed that the percentage of black and Hispanic US medical graduates is 11%. But the percentage of black and Hispanic people in US population is 32%. Andrews point is that medical education leaders are not doing enough to close the gap.
The FDA issued an emergency use authorization for Impella RP for COVID-19 patients with right heart failure. This is classic COVID-19 sciencewhich is not a good thing. Here is a quote from the letter: "Based on extrapolation of data from the approved indication and reported clinical experience, FDA has concluded that the ImpellaRP may be effective at providing temporary right ventricular support for the treatment of acute right heart failure or decompensation caused by COVID-19 complications, including PE [pulmonary embolism]...."
Ive previously discussed the lack of RCT-level data in support of the approved indication for Impella, but lets today focus on the above noted reported clinical experience. One is a case report of 59-year-old woman with COVID-19 and right heart failure due to an acute PE. In 2018, the same group has also reported a series of 5 patients with acute PE and right heart failure treated with the EKOS Endovascular System which delivers low intensity ultrasound for the purpose of facilitated thrombolysis using low dose fibrinolytic therapy. These patients all survived. The endpoints of the case series were hemodynamic measures.
Other data cited in support of the ImpellaRP emergency use authorization (EUA) include alink to an attempted systematic review from Japanese authors who wrote this is in the abstract: The results evidenced that available data are currently scant to definitively assess the real role Impella RP in patient with acute PE and refractory shock.
We could easily have an answer with mechanical circulatory support: the FDA or CMS simply says, if you want reimbursement for this device, do it as part of an adaptive RCT. If it is as good as people think, this would be a small trial.
In a meta-research analysis looking at RCTs in interventional and structural cardiology from 2008 2019, the authors, led by academic heart surgeon Mario Gaudino, studied the association between design, outcome, and reporting of these trials with industry funding.
About half the trials had industry sponsors. Surprisingly, only about half used hard endpoints. And, typical of cardiac RCTs, the mean follow-up was short at one year.
Almost one in five trials was not prospectively registered.
One major discrepancy existed between the registered and published outcomes in 38.0% of the trials.
Commercial sponsorship was associated with statistically significant findings favoring the sponsored treatment; 64% vs 49% with a p-value of 0.02.
Spinlanguage that detracts from a nonsignificant primary endpointwas present in 65%.
Spin was significantly more likely in industry sponsored trials; 80% vs 54%.
This sort of meta-research is not minutia; it is important in the translation of medical evidence at the bedside.
JAMA Internal Medicine also published a Bayesian reanalysis of the EXCEL trial, an RCT comparing left main PCI vs CABG in patients with amenable anatomy. Before you get out of sorts about complexities of the word Bayesian, lets first see how basic it is. First, children are natural Bayesian learners. They constantly use prior information to adjust their behavior. Doctors, too, are natural Bayesians. They also use prior information and adjust the probabilities of something given the prior information.
Bayesian interpretation of trial results differ from the standard null hypothesis significance testing using p-values in that Bayesians estimate the probability of the hypothesis given the results, while we are much more used to the frequentists approach of estimating the probability of the results observed given the hypothesiswhich is usually no difference or null.
In the 5-year EXCEL results, the paper reports that in the primary endpoint, a composite of MACE, the difference was 2.8% higher for PCI. But the confidence intervals ranged from -0.9% reduction to a 6.5% increase and the p-value was nonsignificant. This nonsignificant difference led the authors to conclude that PCI and CABG performed equally well. And then the conclusion was codified in guidelines.
The equivalence was also problematic because the odds ratio for mortality was 38% higher in the PCI arm (difference, 3.1%; 95% CI, 0.2%-6.1%). Recall that the authors of EXCEL argue that the mortality signal is post-hoc subgroup that is underpowered and likely due to chance.
Prof James Brophy from McGill University took the data from EXCEL and previous studies and did a Bayesian analysis. His results are highly notable, not just for deciding on PCI or CABG in left main disease, but more importantly for the interpretation of any clinical trial.
Brophy first took the EXCEL data on its own. You can call this a noninformative prior. He then took an effect size, in this case an increase in 1% mortality with PCI, and used the trial data to calculate its probability. Brophy found a 99% probability that total mortality for patients with left main CAD is increased with PCI and 94% probability that the increased risk exceeds 1%. He did the same for the primary endpoint of MACE: corresponding probabilities for an increase in MACE were 95% and that it was greater than 1% was 87%; and for major adverse cardiac and cerebrovascular events (MACCE), 99.9% and higher than 99%.
Brophy then did the analysis again using the previous studies. For mortality, the probability that PCI increased mortality at all was 85% and that it increased it more than 1% was 47%. For MACE, the probability that PCI increased events was 96% and that it increased it more than 1% was 86%.
One other point that both Brophy and editorialist Sanjay Kaul from Cedars Sinai brought up was that the 3-year EXCEL results were analyzed as a non-inferiority design with the noninferiority margin set at 4.2 percentage points. But then they changed the analysis method at 5 years to superiority. In the 5-year results, the 2.8% higher rate of MACE with PCI had an upper bound of 6%, which would have exceeded the non-inferior margin. Thus, had the EXCEL authors stayed true to their analytic method, PCI would be deemed not noninferior to CABG.
Two of the most respected medical journals have retracted two major observational trials. The Lancet pulled the hydroxychloroquine (HCQ) observational study that got great press and actually caused the World Health Organization to pause the HCQ RCT. And the New Engand Journal of Medicine pulled the study from the same authors on underlying cardiovascular disease and increased risk of COVID-19. That study did not find a harmful association of ACE inhibitors or ARBs.
Retraction of these papers can be directly attributed to sleuth-like investigations from people on Twitter, some with content expertise but others armed only with curiosity. This highlights the value of post-publication peer review. And it should send a warning to healthcare journalists that making conclusions from published papersespecially in the COVID spaceis fraught. Even if these papers were pristine, they were still nonrandomized observational studies and should not be used to shred equipoise or make clinical decisions.
See original here:
Jun 5 2020 This Week in Cardiology - Medscape
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]